BTG International Inc. news

SERB and BTG Specialty Pharmaceuticals are pleased to announce that Thomas Kolaras has been named the group’s new Chief Commercial Officer for its US business.

Thomas is an accomplished commercial leader with more than 25 years of US and global experience across large and mid-sized biopharmaceutical companies. His career includes a wide range of roles in marketing, sales, operations, market access, analytics, finance and business development in over 20 therapeutic categories.

SERB is pleased to announce it has acquired the rights from Ipsen to commercialize Xermelo® (telotristat ethyl) in Europe and other countries outside the US and Japan. Financial terms of the transaction were not disclosed.

Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea (CSD) in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.

“CSD is a debilitating condition that can be difficult to manage

SERB and BTG Specialty Pharmaceuticals announced that the European Commission has granted marketing authorisation for Voraxaze (glucarpidase) to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity. Voraxaze is now authorized for marketing in all members states of the European Union as well as Iceland, Liechtenstein, and Norway. It will be sold in these markets by SERB, which me

The first evidence of high dose methotrexate related toxicity (HDMTX) in Spain was presented today at Virtual ISPOR Europe 2021, a global conference on healthcare economics and outcomes. Xavier Badia, MD, MPH, PhD of Omakase Consulting S.L. presented the poster titled “Epidemiology and Clinical Management of Patients with Methotrexate Toxicity in Spain Using the Delphi Technique,” which shows that 11.6% of patients in Spain treated with HDMTX can be expected to develop acute kidne

SERB and BTG Specialty Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a marketing authorisation for Voraxaze (glucarpidase) to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate